<?xml version="1.0" encoding="UTF-8"?>
<p id="para70">Sex-disaggregated mortality and morbidity surveillance data should be a priority in COVID-19 research.
 <xref rid="bib3" ref-type="bibr">3</xref>, 
 <xref rid="bib5" ref-type="bibr">5</xref> Plans must prioritise protections for participants but account for gender perspectives, lived experiences, and outcomes in research design, intervention, evaluation, interpretation, and dissemination. Immediate research priorities focused on identifying the pathophysiology of the disease and the development of vaccines and therapeutics should give explicit attention to sex differences in viral transmission and disease progression, biological, social, and environmental risks by gender, and safety of vaccines and drugs for pregnant and lactating women.
 <xref rid="bib18" ref-type="bibr">
  <sup>18</sup>
 </xref>
</p>
